TICK-BORNE DISEASES and COVID

NEW CHALLENGES FOR THE CLINICIAN

JOSEPH J. BURRASCANO JR. M.D.

NEW YORK, USA

OUTLINE OF PRESENTATION

- Tick-borne diseases and COVID-19
 - Basics and definitions
 - Similarities and differences
- Laboratory testing for COVID-19
- Early infections- how to differentiate between TBDs and COVID-19
- Chronic cases
 - Could "post-COVID" be reactivated TBDs?
- What happens if your TBD patient gets COVID-19
- Vaccines for COVID-19
- Antibody-dependent enhancement
- Recommendations

What is Lyme Disease?

Today we have a broader definition of "Lyme disease"- We include the common tick-borne co-infections- collectively referred to as "tick-borne diseases" (TBDs)

- Borrelia- Lyme Borrelia and TBRF Borrelia
- Babesia species
- Bartonella-MANY species
- Rickettsias-Ehrlichia, Anaplasma, others
- Viruses

They often coexist ("co-infection")

- Co-infections alter and can blur the clinical presentation
- Co-infections worsen the negative impact on the immune system
- Co-infected patients are more ill and are more difficult to treat

Chronic Lyme- immune impairment that worsens over time

- Lyme-induced immune impairment
 - ► This begins 6 to 12 months into the infection
 - ► Affects all three cell types- B, T and NK cells. Impairs function and may kill them
 - Earlier onset and more severe if co-infected, especially Borrelia + Babesia
- Lyme infections also activate the inflammatory cascade- mini cytokine storm
 - More severe with later, more active infections
 - More severe when co-infected
 - More severe during Herxheimer reactions

LYME- immune effects

Signs that Lyme has weakened the immunity

- Low total WBC counts
- ► Low killer cell (NK-cell) counts
- Decreased immunoglobulin levels (B-cell impairment)
- Impaired T-cell reactivity
- Persistent disease that responds poorly to meds that should work
- Signs that Lyme has activated the cytokines
 - Everything!! The malaise, fatigue, aches, cognitive impairment, neuropathy, arthritis...

WHAT IS COVID-19

It is the disease caused by the coronavirus SARS CoV-2

- Highly contagious, but not everybody gets sick
- Initial viral phase- nonspecific viral symptoms- respiratory and gastrointestinal
- Can be followed by a hyperimmune phase- a runaway immune overreaction resulting in a "cytokine storm"
- Followed by a collapse of T-cell function
- Also associated with significant arterial and venous blood clots, pulmonary fibrosis and decreased oxygen carrying capacity


These non-viral effects cause the severe morbidity and mortality

Lyme and COVID- Similarities and differences

| Tick-borne diseases | COVID-19 |
|--|---|
| Vector-borne | Airborne and surfaces |
| Multiple pathogens | Single virus; multiple variants |
| Blend of infection and inflammation | Viral syndrome can progress to severe cytokine storm |
| Usually begins with mild disease | Usually begins with mild disease |
| Mild-moderate immune impairment in late disease | Severe immune impairment is possible in the very ill |
| Rarely fatal | Wide spectrum from asymptomatic to critical illness and death |
| Treatable | Treatable |
| Chronic forms | Chronic forms |
| No vaccine | Several vaccines |


Laboratory testing for COVID-19

Time course in COVID-19



PCR testing in COVID-19


- RT-PCR is highly insensitive and timedependent
 - ▶ 100% false negative on day 1 of infection
 - 67% false negative on day 4 (the day before symptom onset)
 - 38% false negative on day of symptom onset (day 5)
 - ► 20% false negative on day 8
 - 21% false negative on day 9
 - ▶ 66% false negative on day 21
- "If clinical suspicion is high, infection should not be ruled out on the basis of RT-PCR alone"



Ann Intern Med. doi:10.7326/M20-1495; 13 May 2020

Antibody testing in COVID-19

- One week after symptom onset, IgM appears and persists for 6+ weeks
- IgG appears 1 to 2 weeks after IgM and persists for at least 4 months; declines earlier in the elderly
- False positives because almost half of common colds are due to a mild coronavirus- cross reactivity?
- False negatives- need to turn down test sensitivity to decrease these false positives.
- Immunoblotting may be the answer- more sensitive and more specific
 - Sensitivity: IgM 72.2%; IgG 91.7%; Overall 97.2%
 - Specificity: IgM 99.2%; IgG 98.9%; Overall 98.1%



Testing recommendations- COVID-19

- Tests done in infected but asymptomatic people are usually negative
- For early, symptomatic disease, do nasal swab for PCR
- Saliva testing has not been validated for sensitivity and specificity in early disease
- Be aware of high degree of timing-dependent false PCR readingshighest sensitivity is for several days after symptom onset. Positives outside of this window should be suspect
- Serologies can document prior COVID infection but standard tests are inaccurate
- Immunoblotting
 - more sensitive
 - more specific
 - may be a reasonable alternative to PCR

Differentiating early TBD from early COVID

| Early TBDs | Early COVID |
|--|---|
| Arthropod bite- may be missed | Contagious; may not know source |
| Early Sx nonspecific: headache, fatigue, body aches. May develop a rash | Early Sx nonspecific: headache, fatigue, body aches. Then anosmia, respiratory Sx and fever; may get diarrhea |
| Without proper treatment it becomes musculoskeletal, CNS, PNS and cardiac Migratory and cyclic | May resolve May progress to acute cardiopulmonary disease with severe multiorgan involvement |
| Testing insensitive early in illness | PCR only sensitive during symptoms |



Post-treatment Lyme disease syndrome Post-COVID syndrome ("long haulers")

Many similarities and many differences between chronic Lyme and Post-COVID

- Post-COVID syndrome- many symptoms involving many parts of the body
 - Fatigue, body aches, brain fog; possibly cough, shortness of breath, fever and bowel upset
 - But not all post-COVID patients have respiratory or gastrointestinal symptoms
- Post-COVID pathology can include tissue and organ damage from immune attack, microscopic and macroscopic blood clots, vasculitis and hypoxia
 - ► However, these are not always seen or may be inapparent

QUESTION: Could some Post-COVID cases in fact reflect reactivated Tick-Borne Diseases?

Symptoms common to both

- Fatigue
- ► Headache
- Arthralgias
- Cognitive deficits
- Anxiety, depression
- Sleep difficulties

- Chills
- Sweats
- Shortness of breath
- Cough
- Dizzy
- Palpitations, rapid pulse

Signs common to both

These may be seen in some but not every patient....

- Fever
- False positive Anti Nuclear Antibody
- False positive Rheumatoid Factor
- Anti-phospholipid antibodies
- Activated cytokines
- Abnormal brain scans (MRI, SPECT)

Differentiating late TBD from late COVID

Chronic Lyme

- Prior history of Lyme or tick exposure
- ► Symptoms are migratory and cyclic
- Positive or suggestive tests for TBDs
- Chronic COVID
 - History of prior COVID
 - Symptoms do not migrate or cycle
 - End-organ damage- renal failure, hypoxia, intravascular clots

Clinical evaluation

TEST FOR CHRONIC TICK-BORNE DISEASES

- Indirect + direct tests because of possible immune dysfunction
 - Serology (immunoblots for Borrelia). Look for positive IgM
 - May also add T-cell reactivity assay
 - PCR, FISH; may add antigen capture assay
- Immune dysfunction is common- Measure immunoglobulin levels (Bcells) and T-cell response assay or skin anergy panel.

TEST FOR COVID AND FOR SPECIFIC DAMAGE ASSOCIATED WITH IT

- COVID serology- immunoblot if available; consider PCR
- Arterial oxygen level, chest x-ray, renal function, ferritin
- Consider pulmonary stress test- look for oxygen desaturation



- Careful clinical history can help differentiate TBDs from COVID-19
 - ▶ Be aware of the high incidence of tick-borne co-infections!
 - ▶ If you do not test fully then you can miss an important pathogen
- Testing for COVID worth doing, but PCR may not pick up a late case
 - COVID serology is important, but Immunoblot is preferred to decrease false positives and false negatives
- Test for conditions specific to either one to differentiate them
- Don't exclude the possibility that your patient may have both!

What happens when your Lyme patient gets COVID-19?

Chronic TBDs are associated with depressed immunity

- Concern for worse COVID and reduced vaccine response However- the paradox-
- Most patients with active Lyme seem to resist getting common colds
- In fact, despite the evidence of immune impairment, there does NOT seem to be an increased susceptibility to other infections except the co-infections
- So will the same be true for resistance to COVID?

COVID-19 in LYMEthe Good News

Antibiotics and COVID

- Many antibiotics used in Lyme are also antiviral-tetracyclines, macrolides and azoles
- Most treatments for Babesia are antiviral- those that are based on quinine or artemesia, plus the macrolides that commonly accompany them
- Azole antifungals are also antiviral
- Many complementary treatments used in Lyme are antiviral and/or help the immune system

COVID-19 in LYMEmore Good News

- Survey of several LLMDs all support the finding that COVID is less common in Lyme patients!!
- ▶ If they do become infected with COVID, their course tends to be milder
 - However, most LLMDs will prescribe antivirals for these patients: hydroxychloroquine or ivermectin, plus zinc, vitamins C and D and others
- Nevertheless, the usual COVID risk factors still apply
 - Advanced age
 - Concurrent hypertension, diabetes, obesity
 - Clinical immune deficiency- this is possible in very advanced Lyme
 - Immune suppressive treatments

COVID-19 in Lyme- Suggestions

- Avoid strong Herxheimers if exposed to COVID-19. May need to back off
- Most important is mitochondrial support- vital for healthy immune system
 - ► ATP 360
- Supplemental zinc (antiviral), magnesium and n-acetyl cysteine (dampen cytokine storm); consider artemesia
- Melatonin also for cytokine storm, aspirin to prevent platelet aggregation
- Vitamin C, D and alpha lipoic acid- multiple benefits
- Herbal anti-inflammatories such as quercetin, resveratrol, green tea, sulforaphane, etc.; glutathione for detox and for antioxidant support
 - CytoQuel, Tri-Fortify
- Transfer factors and medicinal mushrooms for NK support
 - Transfer Factor Multi-Immune
- Healthy diet, enforced rest and adequate sleep
- Address fears and anxieties as these can impair immunity
 - ► Counseling, meditation, exercise, etc.

Should my TBD patient get the COVID vaccine?

- Patients with intact immunity generally do have reactions to the vaccine, especially after dose 2
 - Nearly everyone has some type of reaction
 - ▶ Strong reactions in 30%
 - ► Fever, chills, weakness, fatigue, body aches
- TBD patients currently still symptomatic anecdotally react more strongly to the vaccine
- Likelihood and severity of the reaction may depend on the type of vaccine administered
- In theory, one could get ADE ("antibody-dependent enhancement")- cytokine storm from stimulating an already activated immune system

Vaccine types generally available

mRNA

- Induces host cells to create spike protein
- Adenovirus with coronavirus sequences added
 - Adenovirus type 5, 26 or both
 - Chimpanzee adenovirus- concern of development of anti-vaccine antibodies
- Attenuated coronavirus
 - Cultured SARS CoV-2 Whole virus, attenuated
 - Concern about non-neutralizing antibodies re: ADE
- Peptide vaccine
 - Insert SARS CoV-2 genes into virus that infects lab cells which then produce spikeforming proteins. These proteins are assembled into spikes and are injected along with an adjuvant

| VACCINE | EFFIC | ТҮРЕ | ANTIGEN | STORAGE | ADJUVANT | DOSES |
|-----------------------|--------|---------------------------------------|--------------------------|--------------|--------------------------|-----------------------------|
| Moderna | 94% | mRNA | Spike | Freezer | No | 2 |
| Pfizer | 95% | mRNA | Spike | Ultrafreezer | No | 2 |
| Sinovac Coronavac | 78-91% | Inactivated whole Virus | SARS CoV-2 | Refrig | Yes | 2 |
| Sinopharm | 79% | Inactivated whole virus | SARS CoV-2 | Refrig | Ś | 2 |
| Covaxin | Ś | Inactivated Whole Virus | SARS CoV-2 | Freezer | Imidazoquinoline alum | 2 |
| AstraZeneca Oxford | 70-90% | Genetically modified adenovirus | Chimpanzee adenovirus | Refrig | Ś | 2 |
| Sputnik Gamaleya | 91% | Two gen modified adenoviruses | Ad 5 + Ad 26 | Freezer | No* | 2 |
| J & J Janssen | 57-85% | Genetically modified adenovirus | Ad 26 | Refrig | No | One, but studying two |

Antibody dependent enhancement

ADE is a cytokine storm induced by an extreme immune reaction to antigens that it has previously been sensitized to

- multisystem inflammatory syndrome seen in children (MIS-C) is an example of antibody-mediated enhancement- is due to <u>reinfection</u> with SARS CoV-2
- a severe inflammatory state that includes fever, diarrhea, shock, variable presence of rash, conjunctivitis, peripheral edema, vasculitis, thrombosis, mucosal ulcers
 - ▶ in some cases, can lead to multi-organ failure
- the multi-organ failure in MIS-C is manifested by neurologic involvement, hyperferritinemia, and cardiogenic or vasoplegic shock

The potential threat of multisystem inflammatory syndrome in children during the COVID-19 pandemic. Hussin A. Rothan, Siddappa N. Byrareddy. Pediatr. Allergy Immunol. 2021;32:17–22. DOI: 10.1111/pai.13361

Mechanism of ADE in COVID-19

- ▶ With infection, neutralizing and non-neutralizing antibodies are formed
- Neutralizing antibodies inhibit the infection and prevent the spike protein from binding to the ACE-2 receptor
- The non-neutralizing antibodies, when complexed with viral antigen, cause binding of immunoglobulin to macrophage receptors and allow viral entry independent of ACE-2 receptors. This initiates an inflammatory cascade
- It is the balance of the two types of antibodies that determine whether ADE will occur.
- It has been proposed that antibodies to non-spike components of SARS CoV-2 are responsible for this (theory, not proven)

Can COVID -19 vaccines cause ADE?

- If the vaccine has predominantly spike protein as the antigen, then it is unlikely that ADE will result (mRNA vaccines)
- Vaccines made from whole, attenuated coronaviruses or from genetically modified adenoviruses may be more of a risk
 - especially with the second dose or if exposed to SARS CoV-2 after vaccine immunity develops
 - More likely if a previous URI resulted in antibodies in common with that of the vaccine
- Vaccines that contain adjuvants are also of concern
- The above are conjecture only. There has not been enough experience with any of these vaccines to know if these are real risks.

TBD patients and COVID vaccinationrecommendations

- Consider testing for SARS CoV-2 antibodies prior to vaccination to uncover past infection that may have been missed
- Always try to prepare your patient prior to vaccination
 - Detox regimens, ongoing glutathione, quercetin, vitamin C, D and melatonin (typical regimens used to minimize developing a severe form of COVID infection)
 - Gut health- prebiotics and probiotics (RN CoreBiotic, Multi-Biome)
- Do not vaccinate during a symptom flare
 - May have to hold TBD treatment well before vaccination to calm a Herxheimer
- mRNA vaccines may be safer than adenovirus vector-based vaccines
- With couples, stagger vaccination schedules
- Avoid immunosuppression as it may weaken vaccine-induced immunity
- May need to cancel dose-2 but then must follow SARS CoV-2 antibodies

Conclusions

- Many of us are now dealing with two complex conditions-TBDs and COVID-19
- ► They may be difficult to differentiate in certain circumstances
- Both pose challenges for patient management
- COVID-19 vaccination, while beneficial, can be difficult to tolerate in the TBD patient and require careful management pre- and post-dose
- There still are more questions than answers
- I urge everyone to keep track of their data and share it so we all can learn from each other
- Please stay safe!

THANK YOU!